Moderna said on August 23 that it has grabbed Japanese regulatory approval for an updated monovalent formulation of its COVID-19 mRNA vaccine Spikevax that targets the JN.1 variant of the novel coronavirus.The updated jab is intended for use in COVID-19…
To read the full story
Related Article
- Pfizer Earns Japan Nod for JN.1-Adapted COVID Vaccine
August 9, 2024
BUSINESS
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
- Nitto Medic Recalls Heparinoid Lotion over Nitrosamine Impurity
October 14, 2026
- Moderna Rolls Out XFG-Updated Pediatric Spikevax in Japan
October 14, 2026
- Taiho to Take Over Haiyitan Marketing Authorization from Haihe
October 14, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





